![rezafungin](https://www.adcreviews.com/wp-content/uploads/2022/09/rezafungin-240x100.jpg)
FDA Orphan Drug Designation and Fast Track Designation for rezafungin
On September 20, Cidara/Melinta Therapeutics jointly announced that the FDA has accepted the New Drug Application (NDA) for rezafungin (rezafungin) for the treatment of candidemia